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Abstract

Several animal studies have brought the cholinergic hypothesis of
Alzheimer's Disease (AD) into question.

In addition,

recent clinical

studies have shown that the number of neuritic plaques and neurofibrillary
tangles does not yield a conclusive diagnosis of AD.
risk

factors

involved

in

AD

development

has

atherosclerosis is associated with dementia.

A reassessment of

led

to

findings

that

The present study is a

clinical analysis, through the use of case studies, of the relationship
between atherosclerosis severity, based on autopsy results,
severity,

based

on

scores

from

cognitive

assessments, as well as autopsy results.
relates

to

participants

atherosclerosis
at

AD

onset

tests

and

and AD
fu nctional

The age of AD onset as it

has also

been

examined.

The

occurring

with

atherosclerosis

age

has

of

been

determined both through examination of medical records and interviews
with family members.

This is an ongoing study.

Unfortunately, no results

supporting a relationship between atherosclerosis and AD have yet been
found; however, future results may indicate a relationship.
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A Case Study Analysis of the Relationship Between Atherosclerosis and
Alzheimer's Disease
Four

million

Americans

are

currently

afflicted

by

Alzheimer's

disease (AD), and due to an aging population, this number is expected to
increase by 400% in 50 years.

In the U.S., 10% of individuals aged 65 will

develop AD, and 47% of those aged 85 or more will also develop the
disease (de la Torre, 1997; Morrison-Bogorad, Creighton, & Phelps, 1997).
In the general population, there is a 15% lifetime risk of developing AD
(Post et aI., 1997).

Alzheimer's disease affects not only the lives of those

diagnosed but also the lives of both the family and friends who provide
care and support.
The onset of AD is typically marked by a decrease in ability to
recall things such as minor appointments although these initial memory
lapses are generally not noticed by family, friends, and co-workers.

As

the disease progresses, daily life and self care become impaired, and
personality changes begin to occur.

In the final stages of the disease,

speech becomes limited to a single word and then nonexistent.

Movement

ability slowly decays until the patient can no longer hold up their head
(Reisberg, 1988).
The basal forebrain is one of the major areas compromised in AD
(Candy et aI., 1983; Whitehouse, P., Price, D., Struble, R., Clarke, A., Coyle,
J., Delong, M., 1982).

This brain region consists of the medial septal area

(MSA), which sends projections to the hippocampus, and the nucleus
basalis magnocellularis basalis (NMB), which sends projections to the
cortex.

As stated above, one of the first recognized impairments in AD is

memory loss.

Decline in memory is presumably associated with damage to

the hippocampus.

Often the first neuronal structure compromised in AD,

•
Atherosclerosis and Alzheimer's Disease

4

the hippocampus is involved in learning and memory (DeJong, R., 1969;
Garcia, J., 1970; Thomas, G., 1971; Westerhof, P., 1972).
documented

increasing

damage to

the

hippocampus

Braak et al. have
throughout

the

progressive stages of AD.
The nucleus basalis magnocellularis sends projections to both the
amygdala and the cerebral cortex. As part of the limbic system, the
amygdala plays an important role in emotional behavior.

Therefore,

destruction of this neuronal formation could account for changes of
personality noted in AD patients during the later stages of the disease.
The cerebral cortex, particularly the premotor and supplemental motor
cortices of the frontal cortex, is involved in the planning and execution of
movement (Carlson, 1994).

Decline in these functions occurs throughout

the progression of AD, as well.
The basal forebrain accounts for 80-95% of the acetylcholine (ACh)
neurotransmitter in the brain (Dornan et aI., 1996).

As a result, with the

destruction of the basal forebrain comes a depletion of the acetylcholine
neurotransmitter.
"cholinergic

This

hypothesis."

finding
The

has

led to

hypothesis

the development of the
states

that

acetylcholine

decrease, brought on by AD, leads to the cognitive deficits associated
witl, Alzheimer's disease (W. A. Dornan, personal communication, March
1997) .
Many researchers believe that the protein beta amyloid, found in
neuritic plaques, is a primary factor contributing to AD neurodegeneration.
Neuritic plaques (NP) consist of a central beta amyloid (A B) protein core
surrounded by a cluster of dystrophic neurites and activated glial cells.
l\Ieurofibrillary tangles (NFT), of wl,ich tau protein is a major constituent,
are also found consistently in brain regions affected by AD (Cotman and
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The presence of neuritic plaques and neurofibrillary tangles

are considered a neuropathological characteristic of AD.

They are

quantified at autopsy in order to make a definite diagnosis of AD.
However, the criteria used for diagnosis with regards to location and
quantity neuritic plaques and neurofibrillary tangles vary (Tierney, 1988).
Results from histological studies of beta amyloid have been
An in

consistent with the cholinergic hypothesis of AD discussed above.
vivo

study by Harknay, Jong et al. (1995) injected beta amyloid (1-42)

into the medial septal area of rats and found that beta amyloid is
selectively toxic to cholinergic neurons.

GABAergic neurons, also at the

injection site, showed only minor effects.
medial

GABAergic neurons in the

septal area did exhibit some neuritic pruning following

amyloid exposure, a neuronal reaction

beta

also observed in AD patients

(Robakis, 1994).
Additional in vivo
the

nucleus

Histological

basalis
results

experiments involve beta amyloid injections into
magnocellularis,

of these

studies

~Iippocampus,

are

again

or

consistent

ventricles.
with

the

cholinergic hypothesis showing reduced acetylcholine release and reduced
cll0line acetyltransferase and cholinesterase activity in the neural region
exposed to beta amyloid when compared to controls (Abe, Casamenti,
Giovannelli, Scali, Pepeu, 1994; Chen, Harding, Barnes, 1996; Dornan,
Tinkler, Litwiller, Fan, Hanin, at press; Harknay, Lengyel et al.,1995; Itoh,
Nitta et aI., 1996; Maurice, Lockhart, Privat, 1995; Nitta, Itoh, Hasegawa,
Nabeshima, 1994).
choline

Reduced acetylcholine release as well as reduced

acetyltransferase

and

cholinesterase

activity

indicate

degeneration of cholinergic terminals resulting from neurotoxic effects
induced by beta amyloid.

However, one study by Sigurdsson, Hejna, Lee,
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and Lorens (1996) did not find that beta amyloid injections produced
histological signs of toxicity in cholinergic neurons.
While

histological

results

of

beta

amyloid

testing

are

fairly

consistent, behavioral results in studies of the cholinergic hypothesis do
not yield the same consistency.

Among the studies cited above that

included animal behavioral testing, only three showed significant learning
impairment (Itoh et aI., 1996; Maurice et aI., 1995; Nitta et aI., 1994).

The

study by Dornan et al. (in press) resulted in only a marginal effect on
spatial learning following beta amyloid injections, and the Sigurdsson et
al. (1996) study did not find any behavioral affects.
indicate
injection

degeneration
without

associated with AD.

of cholinergic

also

yielding

the

neurons

following

cognitive/learning

These studies
beta

amyloid

impairments

This suggests that the degeneration of cholinergic

neurons may not be responsible for the clinical effects of AD and that the
cholinergic hypothesis is either insufficient or incorrect.
The relationship between the severity of AD dementia and' the
quantity of neuritic plaques and neurofibrillary tangles in the brain is now
being questioned as well.

A study by Snowdon et al. in 1997, know as the

"1\Jun Study" (the participants were all from The School of Sisters of the
Notre

Dame congregation),

found

that among

women

who

met the

neuropathological criteria for AD in terms of the number of neuritic
plaques and neurofibrillary tangles in the brain at autopsy, 31 % did not
have prevalent dementia in life based on cognitive testing (Snowdon et aI.,
1997).

A review by de la Torre states that the density of plaque and

tangle formation in nondemented individuals increases as a 'function of
age, and neuritic plaques and neuro'fibrillary tangles may be found in 100%
of nondemented persons over 80 years old (de la Torre, 1997).

The report
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goes on to suggest that neuritic plaques and neurofibrillary tangles are
products of a neurodegenerative process associated with both AD and also
with normal aging to a lesser extent.
Based on the studies discussed above, a fresh look at the possible
risk factors involved in AD development seems warranted.

History of

cardiovascular disease, stroke, or head trauma have all been implicated as
risk factors (de la Torre, 1997).
found with late-onset AD.
risk factors:

Also, a genetic/familial link has been

Mutations at 3 genes have been identified as AD

1) beta-amyloid precursor protein

(APP), 2) presenilin-2

(PS2) gene, and 3) prensenilin-1 (PS1) gene (Lendon, Ashall, and Goate,
1997; Prince, Cullen, and Mann, 1994).

The PS1 gene mutation is an

exception to the familial late-onset generalization; the mean age of onset
associated with PS1 is 46.8 years (Lopera et aL, 1997).
apopliprotein

In addition, the

E4 allele (apoE 4) has been linked to AD (Evans et aL, 1997;

Gordon, Grauer, Genis, Sehayek, and Michaelson, 1995; Kosunen et aL,
1995; Poirier et aL, 1993).
Apolipoprotein E is a plasma protein that binds to the low-density
lipoprotein (LDL) receptor.

Lipoproteins are plasma proteins involved in

transport of cholesterol and other lipids to and from cells.

Low-density

lipoproteins are rich in cholesterol and are therefore involved in the
growth, repair, and maintenance of myelin and neuronal membranes
following injury (Marieb, 1992; Mahley, 1988).

By binding with low

density lipoprotein receptors, apoE acts to clear low-density lipoproteins
from their binding sites.

This redistributes the lipoproteins into the

blood stream (Mahaley, 1988).

ApoE mRNA plays an important role during

central nervous system (CNS) sprouting and synaptogenesis.

Messenger

RNA is reduced in the hippocampus of AD patients, and in apoE deficient
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mice hippocampal synapse density is reduced (Poirier, Davignon, et aI.,
1993).

These mice also have diminished ability to regenerate synaptic

connections following lesions to the hippocampus.
There are three apoE alleles (E2, E3,

and E4) resulting in six apoE

genotypes (E2/E2, E2/E3, E3/E3, E3/E4, and E4/E4).
E2

has the

lowest

affinity

or the

low-density

Of the apoE alleles,
lipoprotein

receptor,

whereas E4 clears this receptor the most efficiently (Mahley,
However, efficient clearing of cholesterol by apoE 4
neuronal reinnervation following injury.

1988).

could result in poor

Cells rely on cholesterol to build

up membranes, and apoE 4 clears away needed cholesterol from the
receptor too quickly for membrane rebuilding to occur satisfactorily.
Thus, while apoE 4 may clear cholesterol most efficiently, it is also the
least efficient in aiding reinnervation following trauma to the brain.
At the same time, because apoE 4 releases the high cholesterol
lipoprotein from receptors and back in to the bloodstream at a higher rate,
it causes an increase in plasma cholesterol.
have

been

implicated

in

the

Atherosclerosis is a thickening

Increased cholesterol levels

development

of

atherosclerosis.

of the atrial walls causing them

to

protrude into the vessel lumen and possibly occlude the vessel entirely
(Marieb, 1992).
The "response-to-injury" hypothesis is the most commonly accepted
explanation for atherosclerosis development.

This hypothesis states that

an initial event occurs which causes damage to the tunica
endotllelial layer lining blood vessels.

intima., the

An initial event can be brought on

by blood borne cllemicals, viruses, or physical factors such a blow to the
head or hypertension.

Injured endothelial cells of the tunica

intima

release chemotactic agents, and growth factors begin to transport greater
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amounts of cholesterol picked up from the blood in an effort to repair cell
damage. (This involves apoE, and apoE has been shown to upregulate in
response to injury (Hall, Oostveen, Dunn, and Carter, 1995).)

Monocytes

cling to the sites of altered endothelial cells and then migrate beneath the
surface of the tunica intima

where they become macrophages.

Tllese

macrophages are joined by smooth muscle cells which begin moving
toward the intima
and

layer from the tunica media.

macrophages

begin

accumulating

Both smooth muscle cells

cholesterol

appearance of foam cells - the "fatty streak stage."
that the excess plasma cholesterol

and

take

on

the

It is at this stage

resulting from apoE 4 is most

detrimental (Marieb, 1992).
Muscle cells at the intima also deposit collagen and elastin fibers.
These fibers thicken and harden the tunica intima producing lesions 
atherosclerotic plaques.

When fatty mounds of muscle and fibrous tissue

begin to protrude into the lumen of the blood vessel, the individual has
full-blown atherosclerosis.

Eventually, arterial walls become frayed and

ulcerated.

These conditions encourage platlet adhesion and thrombus

formation.

Increased vessel rigidity leads to hypertension, increased risk

of myocardial infarction, stroke, and aneurysm (Marieb, 1992).
Damage to blood vessels when apoE 4 is present might also lead to
an increase in beta amyloid deposition along arterial walls.

A study done

by Hall et al. (1995) induced ischemic trauma for 10 minutes in the
forebrains of gerbils.
followed in the

Beta amyloid protein and apoE activities were then

~Iippocampus

over a period of 7 days.

After two days, a

signi'ficant increase in both beta amyloid and apoE was recorded in the
hippocampus (Hall et aI., 1995).

Results of other studies have shown that

apoE 4 binds to beta amyloid leading to co-deposition of both apoE 4 and
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beta amyloid at the cell (Strittmatter et aI., 1993; Wizniewski, Golabek,
Matsuhara, Ghiso, Frangione, 1993).

It has been hypothesized that the

upregulation of apoE in response to ischemic trauma together with the
binding of apoE 4 and beta amyloid may provide favorable conditions for
the formation of neuritic amyloid deposits.

In additional studies, apoE 4

is associated with reduced cerebral glucose metabolism.

This can lead to

improper splitting of beta amyloid and, therefore, an increase in neuritic
plaque formation (Mier-Ruge, Bertoni-Freddari, Iwangoff, 1994).
In his review article, de la Torre lists four primary changes seen in
the capillary microanatomy of AD patients: 1) thickening of the vessel
wall and the basement membrane, 2) intraluminal distortions produced by
kinking or compression of the abluminial region, 3) endothelial cell
compression with mitochondrial loss, and 4) amyloid deposition in vessel
walls.

Atherosclerosis pathology can lead to all four of these changes.

Additionally, beta amyloid deposited along vessel walls interferes with
the exchange of nutrients and wastes between capillaries and cells, 'and
distorted lumens result in a disturbed blood flow pattern, also making
exchange across the capillaries difficult.

As mentioned above, reduction

of oxygen and nutrients reaching the cells can lead to necrosis (cell death)
as well as the build up of beta amyloid in cells resulting from a shortage
of ATP necessary to properly split the beta-amyloid precursor protein
(Mier-Ruge, Bertoni-Freddari, Iwangoff, 1994).
In a clinical study done by Hoffman et al. (1997), the frequency of AD
and of vascular dementia was found to increase with the degree of
atherosclerosis (mild, moderate, severe).

In the conclusion of this study,

it is stated that dementia, and in particular dementia of the AD and the
vascular type, is associated with atherosclerosis.

It is also concluded
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that there is an interaction found in AD etiology between apoE and
atherosclerosis (Hoffman et aI., 1997).

Another clinical study, this one by

Kosunen et al. (1995), concluded that the apoE 4 allele is associated with
coronary atherosclerosis in elderly AD patients.

This study also states a

lack of associative findings between the extent of coronary or cerebral
atherosclerosis and counts of neuritic plaques.

The study by Kosunen

reinforces the Nun Study, which found that neuritic plaques sufficient for
AD diagnosis did not necessarily coincide with AD dementia.

Such

findings lead to questions about the role of neuritic plaques in AD
dementia just as animal tests investigating the role of acetylcholine in
AD dementia have brought the cholinergic hypothesis into question.
New

avenues

must

be

explored

for

risk

factors

in

AD.

Atherosclerosis is found in association with several forms of dementia
and a study of the relationship between severity of atherosclerosis and
severity of AD dementia, regardless of the number of neuritic plaques
found is warranted.

This study assesses the severity of AD dementia in

relation to severity of atherosclerosis in AD patients as well as the age
of

AD

dementia

onset

when

AD

is

found

in

association

with

atherosclerosis with the expectations that as severity of atherosclerosis
increases, so does AD severity and that AD onset will be earlier when
associated with atherosclerosis.

Methods

Participants
Alzheimer's

disease

can

only

be

definitively

diagnosed

by

postmortem examination of the brain; therefore, autopsy examination of
participants at death is an integral part of this investigation, and brains

Atherosclerosis and Alzheimer's Disease
are procured from all participants who remain in the study.
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Consent for

this procedure is given by legal next-of-kin upon entry into the study, and
results from the brain autopsy are provided to the family free of charge.
The present study is part of an ongoing research project beginning in
1996, and twenty-five participants are currently enrolled in this study.
Eight are now deceased, and autopsy information is available for seven of
these.

Participants may withdraw from the study any time they wish.
This study is being conducted primarily in central

therefore, the majority of the participants live in that area.

Illinois, and,
Overviews of

the IWU brain donor program are given primarily at area hospitals,
schools, nursing homes, etc.

As a result, contact regarding participation

is generally initiated by the family members of those diagnosed with
possible or probable Alzheimer's dementia who have attended these talks.
This also means that participants are diagnosed outside of the study by
primary care physicians or neurologists.

Many of the participants referred

to this program are nursing home residents although some do still live at
home.

Apparatus

and

Procedure

Several assessments of daily living (ADL's) scales as well as
cognitive tests are given to all participants upon entry into the study.

In

addition, care givers are be asked to provide demographic information
about participants, medical histories are gathered, and participants are
assessed by a neuropsychologist for possible depressive disorders (which
may skew cognitive data if present).

Testing is split into two sessions,

separated by a few days, and tests are administered where the participant
resides, at the home or in a nursing home.

The ADL's and cognitive tests

Atherosclerosis and Alzheimer's Disease
are re administered every six months.

13

Cognitive testing may be dropped if

the participant has progressed to severe dementia and is no longer able to
complete these tests, but ADL's are still assessed.
During the first session, ADL's will be filled out by either the
primary investigator (PI) or research assistants with the help of a care
giver, professional or family.
present

at

this

time,

The participant is not required to be

particularly

if

discussion

dementia and declining skill becomes upsetting.

about

progressing

In all, seven ADL's are

given, the Barthel ADL Index, the Brief Cognitive Rating Scale (BCRS), the
Blessed Dementia Scale, the Clinical Dementia Rating (CDR Staging), the
Functional Assessment Staging (FAST), the Global Deterioration Scale
(GDS), and the Modified Rankin Scale (Blessed, G., Tomlinson, B., Roth, M.,
1968; Chino, N., Melvin, J., 1996; Haycox, J., 1984; Reisberg, B., 1988;
Reisberg, B., Ferris, S., de Leon, M., Crook, 1., 1982; Reisburg, B., Schneck,
M., Ferris, S., Schwartz, G., de Leon, M., 1983; Mahoney, R., Barthel, D.,
1965).

Also, the Hachinski Ischemic Score is determined by the Pi in

consultation

with

the

primary

physician

(Hachinski, V., II kff , L., Zilkha, E., 1957).

or

with

medical

history

The Hachinski is used to

determine whether or not the patient has had any transient ischemic
attacks in the past.
After the

ADL's

have

been

'filled

out,

the

Mini-Mental

State

Examination (MMSE) is administered (Folstein, M. Folstein, S., McHugh, P.,
1975).

Cognitive tests are administered by either the PI or by research

assistants trained by neuropsychologists at Bromenn Regional Medical
Center.

Participants are told tl1at tl1ey will be asked questions to test

their memory.

They are instructed that some of these questions are

harder than others and that they are not expected to answer them all
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correctly.

Participants are then be asked if they agree to answer these

questions.

If they respond "yes," they are further instructed that the test

may be halted at any time upon their request.
approximately ten minutes.

MMSE testing lasts

If a participant becomes frustrated with a

question, the researcher moves on to the next question, and if the
participant is unable to complete the test, the reason is noted on the test
sheet and the maximum incorrect score is given for questions not
answered.

Out of a total of thirty points, a score equal to or greater than

twenty-four indicates very mild dementia, a score equal to or greater than
twenty indicates mild dementia, a score of between ten and nineteen
indicates moderate dementia, and a score between zero and nine indicates
severe dementia.
Participants who score in the mild to moderate dementia range
the MMSE are scheduled for a second test.
within a few days or weeks.

011

This is generally scheduled

The Alzheimer's Disease Assessment Scale

(ADAS) is the second cognitive test given, and it is the most widely known
and commonly accepted cognitive test for assessing AD (Mohs, R., Rosen,

W., Davis, K., 1983).

On the ADAS, a score of 0-5 is perfect (no dementia),

6-10 is average, 11-23 is mild, 24-35 is moderate, 36-49 is severe, and
50-70 is very severe. Because the ADAS is a longer and more complicated
test, if a participant scores in the severe dementia range on the MMSE, the
ADAS is not administered.

Test instructions given to the participant and

scoring procedures for a discontinued test are the same as above.

Again,

these tests are administered in either the participant's residence or
nursing home by the PI or by research assistants.
approximately thirty minutes to complete.

The ADAS takes
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At the time of death, either the nursing home or the family of the
participant will contact the funeral home of the family's choice, the
McLean County Coroner's Office, and the PI.
for brain procurement.

Arrangements are then made

The funeral home generally transports the body to

the McLean County Morgue, and brain procurement takes place no longer
than six hours of death with the PI in attendance.

Research assistants

may also be present.
In addition to brain procurement, an initial assessment also takes
place at the McLean County Morgue.

The brain is then taken to the Loyola

University School of Medicine where autopsy is performed.
cut serially in a coronal fashion using a microtome.

The brain is
Sections one

centimeter square are fixed in paraffin to be later stained using Multiple
Luxol Fast Blue/H & E and also Bielschowsky silver.

These stains are used

for diagnostic purposes to reveal amyloid plaques, both diffuse and
neuritic, in the cerebral cortex.

A cryostat is also used to cut smaller

sections of brain (40 microns) which will be frozen and used in future
analysis.

Analysis
Blind to the autopsy results, participant data is separated into
groups based on medical l"Iistory as well as cognitive and functional test
scores.

Data is separated into two groups, probable AD in the absence of

atherosclerosis or probable AD with atherosclerosis.

Once participant

records have been sorted into groups, researcl1er accuracy is tested by
comparing these groups to autopsy reports.
Due to the as of yet small sample size (seven completed autopsy
reports), meaningful statistical analysis is not possible.

Instead, a case
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study for each participant with an autopsy report available has been
written.

Demographic data, medical history, cognitive test scores, and

final autopsy analysis is included.

Qualitative analysis based on these

seven cases has been conducted.

Resu Its
Case One
This 86 year old white male (12/05/09 - 10/07/96) presented with
memory problems that were becoming gradually worse in August of 1991
(at age 81).

Based on a physical workup and an MMSE score in the

moderate to severe range, a preliminary diagnosis of probable AD was
made.

Medical history indicates a recovery from cancer several years

prior.
Patient had 12 years of education and worked as a general yard
master for an oil refinery until his retirement at age 65.

For the last 20

years of his life, he lived in a rural, nonfarm, geographic area.
moved into a nursing home.

In 1996, he

The patient was married at the time of his

death.
When he was diagnosed, the patient was not oriented to date or
month.

He could not spell "train" backwards; however, he could spell

"box" backwards.

Six months following the initial

patient began to show signs of language impairment.

assessment,

the

"[The patient] seems

to search for words and has trouble finishing a thought."

His language

ability continued to deteriorate over the next few months.

At this point,

January 1993, the patient gave up driving.

•
Atherosclerosis and Alzheimer's Disease

17

In December of 1993, this patient was started on Cognex, a drug
developed to help combat dementia.

Five months later, the family

reported noted improvements in the patient's cognition and the dosage
was increased.

However, a few months later family reported resumed

cognitive deterioration.

The patient continued on Cognex until April of

1995, including another dosage increase in January of that same year.
Until April of 1995, the patient's ability to care for himself, home
hygiene and dressing, remained relatively stable.
out for him, he could dress himself.
could no longer dress himself.

If his clothes were laid

By the spring of 1995, however, he

His language abilities had also deteriorated

to "yes" or "no" responses in reply to questions asked of him.
was described as "very confused."

Patient

Later, that year the patient began

"sun-downing," this is when the sleep-wake cycle is disrupted.

He would

awaken in the evenings.
Between April, 1996 and June, 1996, patient was prescribed Haldol,
an antipsychotic, for severe agitation.

The patient was admitted to' the

hospital in June of 1996 with a fractured hip.

Evidence of marked

arteriosclerosis, a vascular disease, was also noted at this time.
patient died in October of this same year.

The

Before his death, the patient's

dementia had progressed to the severe level, with a score of 0/30 on the
MMSE.

He had lost all verbal abilities and was incontinent.

Brain procurement took place October 7, 1996, and the brain was
taken to Loyola that same day.

The brain weighed 1039 grams.

Gross

examination revealed mild focal atherosclerotic plaque in the internal
carotid arteries.

Mild to moderate atrophy was observed throughout the

cerebral cortex.

The amygdala was moderately atrophic bilaterally, while
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the hippocampus showed moderate atrophy on the left and severe atrophy
on the right.
Microscopic examination showed numerous amyloid plaques, both
neuritic and diffuse, and neurofibrillary tangles in all cerebral cortical
areas as well
microscopic

as the amygdala and

neuritic

plaque

and

hippocampus.

neurofibrillary

Tables

tangle

of the

findings

with

respect to location in the brain for all 7 participants are below (Table One
and Table Two).

Final diagnosis for this patient was severe AD, mild

arteriosclerosis, and mild cerebral amyloid angiopathy of the cerebral
cortical and leptomeningial (supply to the hippocampus) blood vessels.

Case Two
T~lis

73 year old white male (8/27/24 - 8/23/97) presented with

confusion, memory problems, and increasing agitation beginning in about
1992, at age 68.

He was brought to a physician in April of 1994 and a

preliminary diagnosis of AD or agitated depression was made.

During the

following month, after a series of tests, depression was ruled out and a
diagnosis of probable AD was given.
Patient had 16 years of education and worked as an undertaker for
about 35 years.

For the last 20 years of his life, he lived in a small city

geographic area (50,000-200,000 population).
nursing home.
When

In 1996 he moved into a

The patient was married at the time of his death.

he was

diagnosed,

the

patient

was

slightly

unkept

appearance and was not performing hygiene activities adequately.

in

He was

disoriented to time, place, and date, and he was unable to give his date of
birth or address.

He also could not name his two children.

The patient's
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speech was clear; however, he did not speak in full sentences, and he
spoke only when asked direct questions.

He had difficulty initiating his

Patient denied any difficulty with

thought and verbalization process.
memory, activities, or behavior.
A

computer

Hemorrhage

in

topography

the

right

(CT)

lateral

intracranial shunt tube was seen.

was

ventricle

conducted
was

in

noted

April
and

1994.
a

right

Overall, no abnormality was identified.

Haldol was prescribed in June of 1994 for agitation.

The prescription was

later discontinued in September, 1996, one month before admission into a
nursing home.
Patient's level of ability in activities of daily living continued to
decline throughout his stay in the nursing home.

Two months before his

death, he required feeding from staff, was incontinent, was unable to
dress himself or find his way to his room, could not walk without
assistance, and his speech was unintelligible.

Before his death, this

patient's dementia had progressed to the severe level with a score of
0/30 on the MMSE.
Brain procurement took place August 23, 1997, and the brain was
taken to Loyola that week.

The brain weighed 1187 grams.

Gross

examination revealed no evidence of atherosclerosis in the intra cranial
blood vessels.

Mild to moderate atrophy throughout the cerebral cortex

was observed.

The amygdala was moderately to severely atrophic

bilaterally, and the hippocampus was moderately atrophic bilaterally.
Microscopic examination revealed numerous diffuse and neuritic
amyloid

plaques

and

neurofibrillary tangles throughout

the

cerebral

cortex, hippocampus, and amygdala. (See Table One and Table Two below.)
Additionally, neuronal loss was observed predominantly in the temporal
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Final diagnosis for this patient was severe AD, and mild focal

cerebral amyloid angiopathy.

Case Three
This 76 year old white female (1/03/21 - 3/05/97) presented with
memory problems that were gradually worsening in June of 1996.

The

patient had a history of clinical depression, seizures, and she

had

experienced head injury with loss of consciousness in a train accident 47
years earlier (1943).

Depression was ruled out as the cause of dementia,

and the patient was admitted to a nursing home.
Patient had 12 years of education, and she worked as a nurses' aid
until her retirement in 1989 at age 68.

For the last 20 years of her life,

she lived in a rural, nonfarm, geographic area.

Patient was never married.

Her family history indicates a brother with memory problems.

Both

parents died of heart failure; however, they were well into their 90'.s at
the time of death.
During her stay in the nursing home, the patient was on Haldol and
Prozac (and antidepressant).

At the time of her death, the patient was

incontinent, had to be bathed and fed, could not find her way to her room,
and was unable to dress herself.

She also had progressed into the severe

range of dementia, scoring 0/30 on the MMSE.
Brain procurement took place March 5, 1997, and the brain was taken
to Loyola that same day.

The brain weighed 1270 grams.

Gross

examination revealed mild atherosclerotic plaque in the internal carotids
and basilar arteries as well as the left vertebral artery.

No gross
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abnormality was observed in the cerebral cortex.
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Both the amygdala and

hippocampus were also unremarkable at gross examination.
Microscopic analysis revealed numerous amyloid plaques, diffuse and
neuritic, throughout all cerebral cortical areas.
were found primarily in the temporal lobe.

Neurofibrillary tangles

The amygdala and hippocampus

both had numerous neuritic plaques and neurofibrillary tangles.
One and Table Two below.)

(See Table

Final diagnosis for this patient was moderate

to severe AD and mild atherosclerosis involving the internal carotids,
basilar, and vertebral arteries.

Case Four
This

85

year

old

wh ite

female

(12/01/11

-

4/05/97)

suffering from gradually worsening dementia in July of 1992.

began

She had a

history of depression, but this was ruled out as the cause of dementia.
The patient also had a history of cancer, arthritis and cataracts.
Patient had over 12 years of education, and she worked as a
secretary until she retired in 1968 at 57 years of age.

For the last 20

years of her life, she lived in a small city geographic area (50,000
200,000

population).

suspected AD.

Family history indicates a paternal

aunt with

Patient's social history shows that she was a smoker for

20-30 years, <1/2 pack per day.
At the time she entered into the study, this patient was unable to
feed or dress herself, was occasionally incontinent, and could not find her
way to her room.

The patient was also showing bellavioral changes, but

she was not taking any medications.
One week after being admitted into the nursing home, patient
became severely dehydrated and had to be hospitalized.

The patient
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She had progressed to severe dementia,

scoring 0/30 on the MMSE.
Brain procurement took place April 5, 1997, and the brain was taken
to Loyola that day.

The brain weighed 920 grams.

Gross examination

showed moderate atherosclerotic plaque of the internal carotids and mild
atherosclerotic plaque of the Circle of Willis and the middle cerebral
arteries.

Moderate to severe generalized atrophy of the cerebral cortex

was observed.

In the temporal lobe, atrophy on the left was more severe

that the right.

Mild to moderate atrophy of the amygdala and severe

atrophy of the hippocampus bilaterally were also observed.
Microscopic analysis revealed numerous amyloid plaques, diffuse and
neuritic,

and

neurofibrillary

tangles

in

all

cerebral

cortical

areas.

Hippocampus examination showed numerous neurofibrillary tangles and
neuritic plaques as did the amygdala.
below.)
moderate

(See Table One and Table Two

Final diagnosis for this patient was severe AD and mild to
atherosclerosis

involving

the

internal

carotids

and

middle

cerebral arteries as well as the Circle of Willis.

Case Five
This 84 year old white male (6/30/12 - 2/24/97) presented with
memory problems in April of 1986 at the age of 83.

The onset of major

symptoms was gradual and impairment became gradually worse.

Four

years later, he was admitted to a nursing home with a diagnosis of
probable AD, Parkinson's, angina, and probable transient ischemic attacks.
Patient had 8 years of education, and he was a farmer for most of
his life until retirement.

For the last 20 years of his life, the patient

lived in a rural, farm, geographic area.

He was married at the time of his
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Family history does not indicate any family members with memory

problems; however, his eldest brother had Parkinson's disease.
At the time he was admitted into the nursing home, this patient was
exhibiting language impairment, behavioral changes, and disorientation to
Over the course of the disease, he became incontinent,

time and place.

unable to feed or clothe himself, and unable to find his way to his room.
By June of 1993, he was totally dependent for all care.
After being admitted into a nursing home, the patient began physical
tllerapy

w~lich

included gait training to improve posture, and balance.

Patient was prescribed Carbidopa for his Parkinsonian symptoms in May,
1996.

This drug appeared to decrease tremors.

observed in October, 1996.

Episodes of apnea were

By the time of his death, the patient had

progressed to severe dementia, scoring 0/30 on the MMSE.
Brain procurement took place February 2, 1997, and the brain was
taken to Loyola the following day.

The brain weighted 970 grams.

Gross

examination revealed moderate to severe atherosclerosis, involving' the
internal carotids,

middle and posterior cerebral, and basilar arteries.

Anterior cerebral and vertebral arteries had mild atherosclerotic plaque.
Mild to moderate atrophy of the cerebral cortex was observed.

Both the

hippocampus and the amygdala were severely atrophic bilaterally.
Microscopic examination revealed numerous amyloid plaques, diffuse
and neuritic, throughout the cerebral cortex.
were noted as well.

Many neurofibrillary tangles

The temporal lobe was most affected.

many neuritic plaques and neurofibrillary tangles.
Table Two below.)

It contained

(See Table One and

Final diagnosis for this patient was severe AD,

moderate to severe cerebral amyloid angiopathy, severe arteriosclerosis,
moderate to severe atherosclerosis, and micro infarction of the remote
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No pathological evidence for Parkinson's

Parkinson-like symptoms were probably due to the

severity of AD combined with vascular disease.

Case Six
This 81 year old white female (1/22/16 - 5/10/97) was found lying
on the floor by a neighbor on August 19, 1994 and was subsequently
110spitalized.

She had been experiencing memory problems for the past

several years, beginning at approximately age 78.

She had a history of

transient ischemic attacks as revealed by her medical charts.

Also, a

1992 carotid Doppler revealed 70-75% stenosis of the left carotid, and
she had a pacemaker.
Patient had 14 years of education, and she worked as a teacher for
some years before becoming a housewife.

For the last 20 years of her

life, she lived in a rural, farm, geographic area.
nursing home in September of 1994.

She was admitted into a

At the time of her death, the patient

was widowed.
While

she was

in the

nursing

home, the

patient

experienced

increasing tearfulness, and she was placed on Pazil, an antidepressant.
She was diagnosed as having a recurrent major depressive disorder.

Her

cognitive abilities continued to deteriorate, and she experienced episodes
of confusion.

A diagnosis of probable AD was made.

The patient was still

able to recognize her daughter and her surroundings.

She was also

ambulatory and could find her way around the nursing home although
episodes of wandering off the premises were noted.

She was not oriented

to date and time, and she required assistance in most of her activities of
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At the time of her death, the

patient had progressed to severe dementia, scoring 3/30 on the MMSE.
Brain procurement took place May 13, 1997, and the brain was taken
to Loyola the same day. The brain weighed 970 grams.

Gross examination

revealed

internal

mild

to

moderate

atherosclerosis

basilar, and vertebral arteries.

in

the

carotids,

Mild atherosclerotic plaque was noted in

the anterior, middle, and posterior cerebral arteries and the Circle of
Willis.

Mild generalized atrophy was observed throughout the cerebral

cortex.

The amygdala was mildly atrophic, and the hippocampus was

moderately atrophic bilaterally.
Microscopic

examination

revealed

numerous

amyloid

throughout the cerebral cortex, mostly of the diffuse type.

plaques

However, the

temporal lobe revealed numerous neuritic plaques and neurofibrillary
tangles.

Neurofibrillary tangles were noted scattered in the frontal and

parietal lobes as well.

Numerous neuritic plaques and neurofibrillary

tangles were observed in both the amygdala and hippocampus.
diagnosis for the patient was moderate AD,

focal

angiopathy

and

involving

leptomeningeal

vessels,

cerebral
mild

to

Final
amyloid

moderate

atherosclerosis.

Case Seven
This

89

year

old

white

female

(10/19/17

-

12/13/96)

began

presenting gradual onset memory problems in the early spring of 1974 at
the age of 66.

These memory problems were becoming gradually worse

although the patient denied confusion.

Her medical history indicates heart

disease hypertension, angina, and seizures.

Early examinations in 1977
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26

By 1985 the diagnosis

had become probable AD.
Patient had 8 years of education, and she was a housewife.

For the

last 20 years of her life she lived in a small city (50,000-200,000
population) geographic area.

In 1985, she was admitted into adult

daycare, and by 1986, she was in long-term care.
death, the patient was widowed.

At the time of her

Family history indicates that her mother

died of a stroke and her father died after a heart attack.
In 1985, the patient began a prescription of Haldol for agitation.
She

experienced

episodes

of

confusion

and

disorientation

to

her

surroundings.

At this time, she was also prescribed Inderal and Digoxen

for her heart.

A CT revealed cortical atrophy, and a later abdominal series

in 1986 revealed evidence of arteriosclerotic vascular disease.
In 1986, after being admitted into long-term care, the patient
experienced much confusion and disorientation.

She could not understand

where she was and why she could not go home.

Her language abilities

continued to deteriorate until she could no longer "make her wants or
needs known," 1994.

She remained ambulatory until 1995.

could walk a few steps with assistance.
dependent in her activities of daily living.

Even then, she

She was however, totally
She was unable to feed and

dress herself or find her way to her room, and she was also incontinent.
By her death, the patient had progressed to severe dementia, scoring a
1/30 on the MMSE.
Brain procurement took place December 13, 1996, and the brain was
taken to Loyola the same day.
examination

The brain weighed 720 grams.

revealed moderate atherosclerotic plaque

Gross

in the internal

carotids, middle and posterior cerebral, basilar, and vertebral arteries.
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Mild generalized atrophy was observed in all cerebral cortical areas.

The

amygdala was mildly atrophic bilaterally, and the hippocampus showed
moderate to severe atrophy bilaterally.
Microscopic examination revealed numerous amyloid plaques, diffuse
and neuritic, and neurofibrillary tangles throughout all cerebral cortica.l
The amygdala showed numerous neurofibrillary tangles,

areas.

hippocampal

examination

revealed

numerous

neuritic

and

plaques

neurofibrillary tangles. (See Table One and Table Two below.)

and
Final

diagnosis for this patient was severe AD, Parkinson's, moderate to severe
arteriosclerosis,

and

moderate

atherosclerosis

involving

the

internal

carotids, middle and posterior cerebral, basilar, and vertebral arteries.

Table One-

Number of Amyloid Plaques (Neuritic Plaques) for Patients

One-Seven

Patient:

One

Two

Premotor:

10 (5)

18 (14)

Frontal:

>30 (>3)

Temporal:

15 (6)

Three

Four

Five

Six

Seven

Area

N/A
>30 (24)

22 (1)

7 (4)

12 (5)

N/A

N/A

>30 (>3)

36 (7)

20 (16)

N/A

20 (16)

25 (6)

20 (12)

20 (18)

N/A

>30
(>27)

Parietal:

8 (6)

>30 (>9)

10 (3)

28 (6)

20 (4)

N/A

>30 (>6)

Occipital:

14 (11)

10 (8)

8 (1)

12 (10)

18 (16)

N/A

10 (8)

22 (20)

15 (11)

8 (6)

N/A

N/A

12 (10)

Amygdala 10 (8)

Number of amyloid plaques per brain region in bold, number of
amyloid plaques which are neuritic in parentheses. (200x Magni'fication)
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Patient:

One

Two

Three

Four

Five

28

a ne- S even
Seven

Six

Area
Premotor:

2

8

0

2

8

N/A

N/A

Frontal:

22

N/A

0

18

23

N/A

46

Temporal:

36

>20

7

26

>40

N/A
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Parietal:

28

13

1

10

22

N/A

24

Occipital:

8

6

0

12

3

N/A

3

Amygdala

24

>30

3

16

N/A

8

Number

of

neurofibrillary

tangles

N/A

per

brain

region.

(200x

Magnification)

The largest number of amyloid plaques among members of this group
appear in the temporal lobe.
behind.

The frontal and parietal lobes are not far

When taking into account the number of these which are neuritic,

the temporal lobe continues to have the highest number (93).

The frontal

lobe (45) again comes in second, along with the amygdala (55) and the
occipital lobe (54), although these are not as close in number to the
temporal lobe as they were when considering the number of plaques
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The parietal does not have a high number of neuritic plaques (34),

comparatively, even though it was among the top brain regions when
considering the number of amyloid plaques.

The premotor cortex has a low

number of both amyloid plaques and neuritic plaques (29).
With the exception of Patient Two, the brain region with the most
neurofibrillary tangles is the temporal lobe in all patients.

Patient Two

has the largest number of neurofibrillary tangles in the amygdala.
should

be

pointed

out that

agitation as part of AD onset.

Patient Two

presented

with

It

increasing

He was also on a prescription of Haldol for

two years.
Average adult brain weight is 1250 grams (V. Hnilika, personal
communication, April 1998).
decreases brain weight.

Atrophy, reported in the case studies above,

Table Three shows brain weights at autopsy for

each of the seven patients and the amount of difference between this
weight and average adult brain weight.

In addition, Table Three lists the

duration of the disease.

Table Three- Duration of AD for Each Patient in Comparison to Decrease
In

. ht f rom Average Ad uIt
Brain
. W'
elg ht , Inferre d f rom DeVlance In Welg

Patient:
Brain

One

Two

Three

Four

Five

Six

1039 gm

1187gm

63 gm

Seven

1270 gm

920gm

970gm

970gm

nOgm

Not

330gm

280gm

280gm

530gm

5 years

1 year

3 years

23 years

(grn):

Difference 211 gm

applicable

(gm):
Duration:

5 years

6 years

1 year

Difference in patient brain weight from average adult in relation to
duration of illness.
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In addition to being analyzed in relation to brain weight, duration of
illness has been analyzed

in relation to cognitive test scores

activities of daily living functional scores.

and

All of the seven patients in

this study were too severely demented to take the ADAS cognitive test;
therefore, only the MMSE was given.
correct score.

On the MMSE, 30 is the maximum

Patients are scored by the number correct out of 30.

Activity of daily living assessments are also included in Table Four.
the Barthel, maximum severity is a score of 0 on a scale of 20.

On

For the

remainder of the activities of daily living assessments, a maximum score
equates to maximum severity (i.e. the higher the score the more severe the
impairment) .

Table

Four- Cognitive Test and Activity of Daily Living Scores in

Relation to Duration of Illness for Each Patient

Patient:

One

Two

Duration:

5 years

6 years

MMSE:

0/30

0/30

0/30

0/30

0/30

3/30

Barthel:

N/A

6/20

N/A

N/A

N/A

N/A

N/A

FAST:

7b17f

7c17f

N/A

6a17f

7f17f

N/A

N/A

Blessed:

N/A

15/17

17/17

N/A

N/A

N/A

16/17

Rankin:

N/A

4/5

N/A

N/A

N/A

N/A

N/A

aDS:

717

717

N/A

617

417

N/A

N/A

Three
1 year

Four
5 years

Five
1 year

Six

Seven

3 years

23 years
1130

As discussed in Methods, this researcher separated patients into
two groups - probable AD with atherosclerosis and probable AD without
atherosclerosis - while still blind to autopsy results.

This assessment
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was done without any medical training and based solely on available
medical records/histories as well as cognitive and functional test scores.
Research assessment in relation to

Assessment was 57% accurate.

autopsy assessment is shown below in Table Five.

Table Five-

Assessment of Research Diagnosis of Patients One-Seven in

Re Iatlon
'
to

Aut opsy D'lagnosls

Patients:

One

Two

Three

Four

Five

Six

Seven

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

Yes

Incorrect

Incorrect

Correct

Correct

Correct

at

AD

Autopsy:
Athero
sclerosis

at
Autopsy:
Correct!

Incorrect

Correct

Incorrect:

Of the incorrect cases above, Patient Three and Patient Four were
placed into the AD without atherosclerosis group by this researcher.
Autopsy

results

atherosclerosis

show

that

present

while

Patient
Patient

Three
Four

did
had

in

fact

mild

to

have

mild

moderate

atherosclerosis present.
Tables Six, Seven, and Eight below deal with the character of AD in
relation to atherosclerosis.

Table Six shows severity of AD in relation to

severity of atherosclerosis.

Table Seven shows patient age at AD onset

with respect to presence or absence of atherosclerosis, and Table Eight
shows length of AD duration, between onset and death, with respect to
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presence or absence of atherosclerosis.
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Dementia for all patients at the

time of death was severe, based on cognitive testing.

Table Six- Severity of AD in Relation to Severity of Atherosclerosis in
Patients One-Seven

Patient:

One

Two

Three

AD

Severe

Severe

Moderate-

severity:

Four

Five

Severe

Severe

Six
Moderate

Seven
Severe

Severe

Athero-

Condition

Condition

sclerosis

not

not

severity:

present

present

Mild

Mild-

Moderate-

Mild-

Moderate

Severe

Moderate

Moderate

Table Seven- Age at AD Onset with Respect to the Presence or Absence
of Atherosclerosis

Patient:
Age

at

One

Two

Three

Four

Five

Six

Seven

81

67

75

80

83

78

66

No

No

Yes

Yes

Yes

Yes

Yes

N/A

N/A

Mild

Onset:
Athero
sclerosis?:
Severity
of Athero-

Mild-

Moderate-

Mild-

Moderate

Severe

Moderate

sclerosis:

Severity of atherosclerosis, when present, given for reference.

Moderate
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Table Eight- Duration of AD with Respect to the Presence or Absence of
Atherosclerosis

Patient:

One

Two

Duration

5 years

6 years

No

N/A

Three

Four

Five

Six

Seven

1 year

5 years

1 year

3 years

23 years

No

Yes

Yes

Yes

Yes

Yes

N/A

Mild

of AD:
Athero
sclerosis?:
Severity
of Athero-

Mild-

Moderate-

Mild-

Moderate

Severe

Moderate

Moderate

sclerosis:

Severity of atherosclerosis, when present, given for reference.

Out of five severe AD cases, atherosclerosis was found in three.
these

three,

atherosclerosis

moderate-severe.

severity

ranged

from

mild-moderate

Of
to

Duration of the disease in the moderate-severe case

was only one year, much shorter than the other two severe AD cases with
associated atherosclerosis.

However, of these two remaining cases, the

mild-moderate case,

Patient 7, had a longer duration than the mild

atherosclerosis case.

Also, the two cases of AD without atherosclerosis

had similar durations to the AD with mild-moderate atherosclerosis case.
One final note, four out of seven patients showed cerebral amyloid
angiopathy at autopsy.

This is deposition of beta amyloid along blood

vessel walls and is consistent with the study by Hall et al. discussed
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Table Nine shows the severity of cerebral amyloid angiopathy, if

present, for all seven patients in relation to severity of AD, age at AD
onset, and duration of AD.

I 'd Anglopat hIy
T a bl e N"me- C ere braI A mylol

Patient:

One

Two

Mild

CAA

Mild

Severity:
Severe

AD

Severe

Severity:

Three

In

Re Iatlon
'
to AD

Four

Five

Not

Not

Moderate-

Present

Present

Severe

Moderate-

Severe

Severe

Six

Seven

. Mild

Not
Present

Moderate

Severe

Severe

AD

5 years

6 years

1 year

5 years

1 year

3 years

23 years

81

67

75

80

83

78

66

Duration:
Age at AD
Onset:

Cerebral Amyloid Angiopathy is abbreviated as (CAA).

Discussion
Alzheimer's research has explored many avenues over the c ourse of
the years in search of a cause and ultimately a cure.

Two such avenues

have been discussed in this paper, the cholinergic hypothesis and the
hypothesis

relating

to the quantity

present in the brain.
failed

to

find

of

beta

amyloid/neuritic

Behavioral studies of the cholinergic hypothesis

learning deficiencies associated with the

neurotransmitter in rats.

plaques

acetylcholine

These findings cast doubt on the theory that

lowered acetylcholine levels are the underlying cause of AD dementia.
With regard to the quantity of neuritic plaques in the brain and their
association with AD and AD dementia, criteria for the number of neuritic
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present

and

in what

areas

of the

brain

are
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not definite.

Additionally, Snowdon et al.'s "Nun Study" found that a diagnosis of AD
could be made at autopsy on the basis of neuritic plaque findings without
any corresponding in-life dementia.
The present study showed a wide number range of neuritic plaques
in those diagnosed with severe AD (39-75 neuritic plaques), and only as
little as 25 neuritic plaques were needed for a diagnosis of moderate
severe AD.

Similarly, in those diagnosed with severe AD, the number of

neurofibrillary tangles ranged from 84-120, while a moderate-severe AD
diagnosis had as little as 11

neurofibrillary tangles.

It is, however,

interesting to note that the greatest number of neuritic plaques overall
were found in the frontal and temporal lobes as well as in the amygdala,
areas which are most affected by AD.

Also, all patients had the greatest

number of neurofibrillary tangles in the temporal lobe except one.

Patient

Two had the largest number of neurofibrillary tangles present in the
amygdala.
Problems with the cholinergic hypothesis and the variable findings
in neuritic plaque quantification studies have led to a reexamination of AD
risk factors so that perhaps a new hypothesis of AD development and
dementia can be constructed.

The hypothesis of AD development and

dementia examined in this study was that of the relationship between
atherosclerosis and AD.

In particular, atherosclerosis severity and AD

severity, as well as, atherosclerosis as it relates to AD onset were
examined.
Researcher assessment and grouping of patients prior to knowledge
of autopsy diagnosis was fairly accurate, 57%.

That these assessments

were made only with available records with out medical training

is
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If a link between AD and atherosclerosis is established,

diagnosis of living patients by trained professionals should be very
accurate and could eventually aid in AD treatment.
Unfortunately, this study has not established any link between
atherosclerosis and AD.

Because this was a case study analysis,

statistics could not be used.

Furthermore, inferences about AD as it

relates to atherosclerosis could not be drawn from data gathered on these
seven patients.
The range of severity of atherosclerosis corresponding with severe
AD is too wide to be meaningful.

In addition, atherosclerosis was not

present in two out of five severe AD cases.

When looking at duration of

illness, severe AD with moderate-severe atherosclerosis has the lowest
duration, one year.

However, mild-moderate atherosclerosis with severe

AD has a much shorter duration than moderate atherosclerosis with severe
AD, 5 vs. 23 years.

Also, the duration of severe AD with mild-moderate

atherosclerosis is 110 different than that of Patients One and Two who, had
no associated atherosclerosis.

Finally, there are no patterns between age

of AD onset and presence of atherosclerosis in this data set.

Based on

these results, no meaningful statements about the relationship between
AD and atherosclerosis can be made.
A slight increase in differential brain weights between average
adults and AD patients can be seen as AD illness duration increases.

Data

do not indicate a relationship between duration of illness and cognitive
test scores.

All patients scored in the severe AD dementia range

regardless of AD duration.

Also, there does not appear to be a link

between cerebral amyloid angiopathy and AD severity at this point in the
study.

Atherosclerosis and Alzheimer's Disease

37

It should be noted once again that this data set is extremely small.
The number of participants in the study continues to grow, and eventually
statistical analyses will be available.

At that point, a pattern between

AD and atherosclerosis may begin to emerge.

For the time being, the small

data set is a severe limitation to this study.
Continuous testing of participants every six months and performing
a brain autopsy on all participants at the time of death are methods not
common in the current literature on AD and atherosclerosis.

This study

has the potential to advance knowledge of AD when it is finally brought to
its conclusion.

Future researchers may wish to track the time between

onset and significant downturn of cognitive abilities in AD patients when
atherosclerosis is present.
cerebral

amyloid

angiopathy

Finally, a more extensive examination of
and

its

relation

to

atherosclerosis severity could be added in the future.

AD

severity

and
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